BACE1 and Alzheimer disease: Three caffeic acid–RSV hybrid derivatives (compounds 1–4) showed superior inhibition of the key AD enzymes, beta amyloid cleaving enzyme 1 (BACE1) and AChE, compared with the parent compounds and standard drugs.